NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $60.51 -0.25 (-0.41%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$60.06▼$61.6550-Day Range$56.43▼$65.7252-Week Range$48.20▼$70.81Volume409,932 shsAverage Volume192,055 shsMarket Capitalization$1.27 billionP/E Ratio37.82Dividend YieldN/APrice Target$82.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get ANI Pharmaceuticals alerts: Email Address ANI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside36.8% Upside$82.75 Price TargetShort InterestBearish7.96% of Shares Sold ShortDividend StrengthN/ASustainability-2.48Upright™ Environmental ScoreNews Sentiment0.84Based on 2 Articles This WeekInsider TradingSelling Shares$4.09 M Sold Last QuarterProj. Earnings Growth12.57%From $3.50 to $3.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.39 out of 5 starsMedical Sector93rd out of 910 stocksPharmaceutical Preparations Industry36th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.96% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 439.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.48. Previous Next 2.1 News and Social Media Coverage News SentimentANI Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ANI Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,091,535.00 in company stock.Percentage Held by Insiders12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 12.57% in the coming year, from $3.50 to $3.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 37.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 37.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About ANI Pharmaceuticals Stock (NASDAQ:ANIP)ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More ANIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Stock News HeadlinesAugust 15, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $14,905.00 in StockAugust 29, 2024 | americanbankingnews.comShort Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Expands By 439.8%September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 29, 2024 | americanbankingnews.comStockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to HoldAugust 28, 2024 | msn.comANI Pharmaceuticals, Inc. (ANIP): A Cheap Pharmaceutical Stock to Buy According to Short SellersAugust 21, 2024 | uk.finance.yahoo.comANI Pharmaceuticals Inc (BSFA.DU)August 14, 2024 | finance.yahoo.comANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Of Questionable QualityAugust 13, 2024 | globenewswire.comANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers' Option to Purchase Additional NotesSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 9, 2024 | seekingalpha.comANI Pharmaceuticals, Inc. (ANIP) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | globenewswire.comANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes OfferingAugust 7, 2024 | marketwatch.comANI Pharmaceuticals Shares Drop 8% After Private Notes OfferingAugust 7, 2024 | markets.businessinsider.comANI Pharma To Offer $250 Mln Of Convertible Senior Notes Due 2029, Stock DownAugust 7, 2024 | globenewswire.comANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes OfferingAugust 6, 2024 | msn.comANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024August 6, 2024 | globenewswire.comANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 GuidanceJuly 15, 2024 | globenewswire.comANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral PowderJuly 2, 2024 | globenewswire.comANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USPSee More Headlines Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year FoundedN/APrice Target and Rating Average Stock Price Target$82.75 High Stock Price Target$94.00 Low Stock Price Target$77.00 Potential Upside/Downside+36.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.60 Trailing P/E Ratio37.82 Forward P/E Ratio17.29 P/E GrowthN/ANet Income$18.78 million Net Margins5.01% Pretax Margin6.59% Return on Equity15.64% Return on Assets7.63% Debt Debt-to-Equity Ratio0.62 Current Ratio3.97 Quick Ratio3.07 Sales & Book Value Annual Sales$538.95 million Price / Sales2.35 Cash Flow$6.09 per share Price / Cash Flow9.93 Book Value$21.66 per share Price / Book2.79Miscellaneous Outstanding Shares20,973,000Free Float18,309,000Market Cap$1.27 billion OptionableOptionable Beta0.75 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Nikhil Lalwani (Age 46)President, CEO & Director Comp: $2.32MMr. Stephen P. Carey (Age 53)Senior VP of Finance & CFO Comp: $1.11MMr. Chad Gassert (Age 48)Senior Vice President of Corporate Development & Strategy Comp: $849.71kMr. Christopher K. Mutz (Age 52)Senior Vp & Head of Rare Disease Comp: $867.92kMr. Ori Gutwerg (Age 49)Senior Vice President of Generics Comp: $895.16kMr. Muthusamy Shanmugam MS R.Ph. (Age 56)Head of R&D, COO of Novitium Operations & Director Mr. James G. Marken (Age 61)Senior Vice President of Operations & Product Development Comp: $673.23kMs. Meredith W. Cook (Age 49)Senior VP, General Counsel & Corporate Secretary Ms. Krista L. Davis (Age 50)Senior VP & Chief Human Resources Officer Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare DiseaseMore ExecutivesKey CompetitorsConcert PharmaceuticalsNASDAQ:CNCEProgenics PharmaceuticalsNASDAQ:PGNXSelecta BiosciencesNASDAQ:SELBCytomX TherapeuticsNASDAQ:CTMXDURECTNASDAQ:DRRXView All CompetitorsInsiders & InstitutionsAlgert Global LLCSold 23,629 shares on 8/16/2024Ownership: 0.062%Marathon Capital ManagementSold 875 shares on 8/15/2024Ownership: 0.335%The Manufacturers Life Insurance Company Bought 1,211 shares on 8/15/2024Ownership: 0.045%Deerfield Management Company L.P. Series CBought 511 shares on 8/15/2024Ownership: 0.024%Susquehanna Fundamental Investments LLCBought 3,588 shares on 8/15/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $55.14 at the start of the year. Since then, ANIP stock has increased by 9.7% and is now trading at $60.51. View the best growth stocks for 2024 here. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Tuesday, August, 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals's revenue for the quarter was up 18.5% on a year-over-year basis. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. Who are ANI Pharmaceuticals' major shareholders? Top institutional shareholders of ANI Pharmaceuticals include Dimensional Fund Advisors LP (3.00%), Rubric Capital Management LP (2.88%), William Blair Investment Management LLC (2.33%) and Millennium Management LLC (1.10%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Chad Gassert, Stephen P Carey, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Antonio R Pera, Krista Davis, Jeanne Thoma, Thomas Haughey and Patrick D Walsh. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA) and Broadcom (AVGO). This page (NASDAQ:ANIP) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free anip Stock Alerts